ArticleFrontiers in medicine2026
Blood inflammatory markers combined with tumor markers for differentiating benign prostatic hyperplasia from prostate cancer.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate cancer (PCa) is the second most frequently diagnosed malignancy in men worldwide, whereas benign prostatic hyperplasia (BPH) is among the most prevalent non-malignant prostatic disorders. Differentiating between these two conditions remains challenging because of overlapping clinical manifestations and the limited specificity of currently available biomarkers. Methods: This retrospective study enrolled 200 male patients (53 PCa, 147 BPH) who underwent prostate biopsy or surgical resection based on pathological diagnosis. Clinical characteristics, laboratory parameters, and inflammatory indices were compared between the groups. Both univariate and multivariate logistic regression analyses were conducted to identify independent predictors. Nomograms were developed and validated through calibration curves, ROC analysis, and decision curve analysis (DCA). Results: PCa patients had significantly higher levels of inflammatory markers than BPH patients ( Conclusion: Blood inflammatory markers, particularly AISI, in combination with conventional biomarkers, offer enhanced diagnostic accuracy for differentiating BPH from PCa, representing a non-invasive and cost-effective approach for clinical decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.